AUTHORS
Madhuri Paul, PhD, Timothy J. Stuhlmiller, PhD2, John M. Furgason, PhD3, Frank Scarpa, MS4, Qin Tang, PhD5, Hiba Kouser6, Jacob Hendershot7, Roisin Puentes, PharmD, PhD8, Derek Lyle, MD9
AFFILIATIONS
1 NeoGenomics Laboratories, Aliso Viejo, United States
2 xCures, Oakland, California, United States
3 NeoGenomics Laboratories, Aliso Viejo, United States
4 NeoGenomics Laboratories, Aliso Viejo, United States
5 NeoGenomics Laboratories, Aliso Viejo, United States
6 xCures, Oakland, California, United States
7 xCures, Oakland, California, United States
8 NeoGenomics Laboratories, Aliso Viejo, United States
9 NeoGenomics Laboratories, Aliso Viejo, United States
ABSTRACT
Background: TP53 abnormalities, including TP53 mutations and del(17p), are established adverse prognostic markers in chronic lymphocytic leukemia (CLL), influencing disease biology, treatment response, and outcomes. Recent classifications distinguish TP53-abnormal disease into single-hit (SH) and multi-hit (MH) categories, but their genomic and clinical significance in large real-world CLL cohorts remains incompletely defined.
Methods: We performed a retrospective clinicogenomic analysis of 5,363 patients with CLL by integrating NeoGenomics molecular profiling data with longitudinal clinical data extracted from electronic medical records through the xCures platform. Patients were classified as TP53 wild-type (WT) or TP53-abnormal based on the presence of TP53 mutations and/or del(17p). TP53 variants were categorized as pathogenic/likely pathogenic (P/LP) or variants of uncertain significance (VUS). TP53-abnormal patients were further stratified into SH disease, defined as a single TP53 mutation or isolated del(17p), and MH disease, defined as multiple TP53 mutations or concurrent TP53 mutation and del(17p). Genomic alterations, biologic features, disease status, and treatment patterns were compared across TP53 subgroups using chi-square or Fisher’s exact tests. Overall survival (OS) was evaluated using linked EMR and mortality data. OS was estimated using the Kaplan-Meier method, compared using the log-rank test, and hazard ratios (HRs) were calculated using Cox proportional hazards models.
Results: Among 5,363 patients with available TP53 testing, 4,818 (89.8%) had TP53 WT disease and 545 (10.2%) harbored TP53 alterations, including del(17p). Among TP53-abnormal cases, 504 carried P/LP TP53 mutations and 26 had VUS. Overall, 508 patients (9.5%) were classified as SH and 104 (1.9%) as MH. A stepwise enrichment of adverse biologic features was observed across TP53 subgroups. IGHV-unmutated disease increased from 738 WT (15.3%) to 103 SH (20.3%) and 23 MH (22.1%) patients, while complex karyotype increased from 31 WT (0.6%) to 21 SH (4.1%) and 5 MH (4.8%) patients (both P<0.001).
Distinct genomic profiles emerged across TP53 subgroups. WT disease was enriched for chromosome 12/13 deletions (n=3,882, 80.6%), IGHV mutations (n=1,697, 35.2%), ATM (n=807, 16.8%), NOTCH1 (n=607, 12.6%), TET2 (n=433, 9.0%), and SF3B1 mutations (n=377, 7.8%). SH and MH disease demonstrated similar genomic landscapes enriched for adverse alterations, including chromosome 12/13 deletions (75.8% and 76.9%, respectively), chromosome 11 deletions (65.0% and 55.8%), and IGHV mutations (27.2% and 27.9%). SH disease was additionally characterized by BTK mutations (n=78, 15.4%), 6q deletions (n=71, 14.0%), and SF3B1 mutations (n=68, 13.4%), whereas MH disease more frequently harbored ATM mutations (n=25, 24.0%), BTK mutations (n=23, 22.1%), and 6q abnormalities (n=24, 23.1%). Notably, BTK mutations were markedly enriched in TP53-abnormal disease (15.4% SH, 22.1% MH vs 1.7% WT).
Disease status information was available for 2,871 WT, 337 SH, and 71 MH patients. Recurrent disease increased with TP53 disruption, occurring in 6.0%, 7.4%, and 11.3% of WT, SH, and MH patients, respectively (P=0.005). Treatment information was available for 3,262 WT, 382 SH, and 73 MH patients. Targeted therapy use was higher in TP53-abnormal patients (19.2% WT vs 41.4% SH and 41.1% MH), while chemotherapy use increased progressively (5.7%, 14.4%, and 21.9%, respectively; P<0.001). Among 1,932 patients with available survival data, TP53-aberrant disease was associated with significantly inferior OS compared with TP53 WT disease (HR 1.91, 95% CI 1.18-3.11; log-rank P=0.008).
Conclusions: TP53 abnormalities were identified in approximately 10% of patients in this large real-world CLL cohort and were associated with enrichment of adverse biologic features. While SH and MH disease shared broadly similar adverse genomic landscapes, both were enriched for chromosome 11 deletions, 6q abnormalities, and particularly BTK mutations relative to WT disease. The marked enrichment of BTK mutations among TP53-abnormal patients suggests a potential relationship between TP53 disruption and BTK-altered disease biology. Collectively, these findings indicate that TP53 hit status is associated with progressively adverse biologic and clinical features, increased therapeutic intensity, and inferior survival outcomes, supporting its utility for risk stratification and therapeutic decision-making in CLL.
DISCLOSURES
Madhuri Paul, PhD: NeoGenomics Laboratories, Inc. - Current Employment